KALETRA 200-50 MG TABLET

Lopinavir and Ritonavir
$8.3041per EA

Strength

200; 50 mg/1; mg/1

Manufacturer

AbbVie Inc.

NDC

00074679922

Classification

Brand

Dosage Form

TABLET, FILM COATED

Route

ORAL

Last Updated

5/22/2024

Active Ingredients

LOPINAVIR; RITONAVIR

Approval Type

New Drug (NDA)

FDA Application

NDA021906

On Market Since

6/18/2010

Pharmacological Classes

Breast Cancer Resistance Protein Inhibitors
Cytochrome P450 1A2 Inducers
Cytochrome P450 2B6 Inducers
Cytochrome P450 2C19 Inducers
Cytochrome P450 2C9 Inducers
Cytochrome P450 2D6 Inhibitors
Cytochrome P450 3A Inducers
Cytochrome P450 3A Inhibitor
Cytochrome P450 3A Inhibitors
Cytochrome P450 3A Inhibitors
Cytochrome P450 3A4 Inhibitors
HIV Protease Inhibitors
HIV Protease Inhibitors
Organic Anion Transporting Polypeptide 1B1 Inhibitors
P-Glycoprotein Inhibitors
P-Glycoprotein Inhibitors
Protease Inhibitor
Protease Inhibitor
UDP Glucuronosyltransferases Inducers

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

0.0%

3Y

+0.5%

5Y

+0.5%

All

+33.2%